Trial
NCT01866423
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.
Condition
Adenocarcinoma of the Prostate
Intervention
orteronel
Why stopped
Not progressing toward scientific goals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-31